Palbociclib is an orally administered inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), enzymes that promote entry into the cell cycle and become dysregulated in many cancers (Asghar, Witkiewicz, Turner, & Knudsen, 2015). The gene discussed is CDK4; the disease is cancer.